How is ZAP‑X stereotactic radiosurgery indicated and planned for patients with limited brain metastases (up to three lesions, each ≤4 cm) and good performance status?

ZAP-X Stereotactic Radiosurgery for Limited Brain Metastases

ZAP-X is an appropriate stereotactic radiosurgery platform for treating patients with 1-4 brain metastases (each ≤3-4 cm) and good performance status (KPS ≥70), following the same evidence-based principles established for other SRS systems.

Patient Selection Criteria

For ZAP-X treatment, select patients meeting these specific parameters:

• Number of lesions: 1-4 unresected brain metastases 1, 2
• Lesion size: Each metastasis ≤3-4 cm in maximum diameter 1, 2
• Performance status: KPS ≥70 or ECOG PS 0-2 1, 2
• Histology: All histologies except small-cell carcinoma (which requires different management) 1
• Systemic disease: Patients should have systemic therapy options available 1

Critical exclusion: Do not offer radiation therapy to patients with KPS ≤50, as they will not benefit within a meaningful timeframe 1.

Treatment Planning Approach

SRS Alone vs. WBRT Combination

Offer SRS alone without whole brain radiation therapy (WBRT) for this patient population 1, 2. The evidence strongly supports this approach:

• No survival detriment: Withholding upfront WBRT does not compromise overall survival 2
• Neurocognitive preservation: SRS alone causes significantly less neurocognitive decline and better quality of life compared to WBRT 2
• High local control: SRS alone achieves excellent local control rates for appropriately selected lesions 2

Trade-off to discuss with patients: While WBRT provides better distant brain control and reduces need for salvage therapy, the neurocognitive cost outweighs this benefit for most patients with limited metastases 2.

ZAP-X Technical Specifications

ZAP-X is a novel, self-shielded gyroscopic radiosurgery system validated for clinical use 3. Key technical characteristics:

Dosimetric Performance

• Dose gradient: ZAP-X demonstrates superior dose falloff (better gradient index) compared to CyberKnife, particularly for lesions <10 cc 4, 5
• Conformity: Slightly inferior conformity compared to CyberKnife and Gamma Knife, especially for very small (<1 cc) or large (>10 cc) targets 4, 5
• Homogeneity: Depends significantly on isocenter placement technique; requires experienced planning 4

Treatment Efficiency

• Treatment time: Comparable to other SRS platforms 4, 5
• Collimation: Uses circular collimators (7.5-25 mm); delivery efficiency depends on collimator size selection 4, 3

Clinical Validation

The ZAP-X treatment planning system has been validated through comprehensive commissioning showing:

• Point-dose measurements within ±4% for collimators 10-25 mm 3
• Film-based patient QA averaging 98.7% gamma passing rate (2%/2 mm) 3
• End-to-end testing confirms accuracy for clinical use 3

Prescription Dosing

Single-fraction SRS dosing (based on established SRS principles, applicable to ZAP-X):

• Prescription to 50% isodose line is acceptable 6
• Typical prescription: 13-23 Gy single fraction for small metastases 6, 5
• Optimize prescription isodose to 97-100% target coverage 4

Fractionated SRS consideration: For larger lesions approaching 4 cm or those near critical structures, consider fractionated approaches (e.g., 30-36.5 Gy in multiple fractions) 7, 5.

Treatment Planning Algorithm

1. Acquire high-quality imaging: CT with MRI fusion for target delineation 3
2. Define planning target volume: Ensure D99.5% receives prescription dose 5
3. Select collimator sizes: Choose based on target size; multiple collimators may be needed 4, 3
4. Optimize isocenter placement: Critical for homogeneity with ZAP-X; use multiple isocenters for irregular targets 4
5. Verify dose constraints: Ensure organs at risk meet standard SRS constraints 4
6. Independent dose verification: Use RadCalc or similar for monitor unit verification 3
7. Patient-specific QA: Perform film-based verification (target >95% gamma passing at 2%/2 mm) 3

Clinical Outcomes Expectations

Based on limited early ZAP-X data and established SRS principles:

• Tumor control: Expect 31-56% volume reduction at 8 months 6
• Symptom improvement: Most patients experience symptom resolution or stabilization 6
• Safety profile: No major complications reported in early series 6

Important Caveats

Multidisciplinary coordination: Manage these patients through a multidisciplinary team including neurosurgery, radiation oncology, and medical oncology 1, 8.

Surgical consideration: For lesions approaching 4 cm, strongly consider surgical resection first, as single-fraction SRS shows lower local control for larger lesions 2.

Systemic therapy integration: Coordinate timing with targeted therapy or immunotherapy, though optimal sequencing remains under investigation 7.

Follow-up protocol: Serial MRI imaging is essential to monitor response and detect new lesions requiring salvage treatment 6.